Abstract Library

#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy

Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Strosberg J

Authors: Strosberg J, Cives M, Brelsford M, Black M, Meeker A,

Keywords: ki67, MGMT, ALT, chromosomal instability, temozolomide, capecitabine, pNET,

#826 Correlation of Serum Chromogranin A Change with Radiographic Response in Patients with Non-Functioning Advanced Neuroendocrine Tumors

Introduction: Numerous studies have suggested that CgA determination may be useful for the diagnosis and follow-up of neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Cheng Y, Sun Z, Bai C, Ying H, Meng C,

Keywords: CgA change, radiographic response, nonfunctioning NETs,

#449 Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report

Introduction: Thymic neuroendocrine tumors are rare, with an estimated annual incidence of 0.2 per million. They are generally considered chemoresistant and there have been no reported cases of an objective response to therapy.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: SarangaPerry V, Morse B, Kvols L, Strosberg J,

Keywords: neuroendocrine tumor, thymus, capecitabine, temozolomide,

#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors

Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Strosberg J, Cheema A, Campos T, Kvols L,

Keywords: transarterial embolization, sunitinib, progression-free survival,